CY1122572T1 - Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögren - Google Patents
Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögrenInfo
- Publication number
- CY1122572T1 CY1122572T1 CY20191101354T CY191101354T CY1122572T1 CY 1122572 T1 CY1122572 T1 CY 1122572T1 CY 20191101354 T CY20191101354 T CY 20191101354T CY 191101354 T CY191101354 T CY 191101354T CY 1122572 T1 CY1122572 T1 CY 1122572T1
- Authority
- CY
- Cyprus
- Prior art keywords
- sjögren
- trifluoroethyl
- syndrome
- treatment
- specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η Ν-{(R)-1-[8-χλωρo-2-(1-oξυπυριδιv-3-υλo)-κιvoλιv-3-υλo]-2,2,2-τριφθoρoαιθυλo}-πυριδο[3,2-d]πυριμιδιν-4-υλαμίνη είναι αποτελεσματική στη θεραπεία ή/και την πρόληψη του συνδρόμου Sjögren.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1506786.1A GB201506786D0 (en) | 2015-04-21 | 2015-04-21 | Therapeutic use |
PCT/EP2016/058810 WO2016170014A1 (en) | 2015-04-21 | 2016-04-20 | A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122572T1 true CY1122572T1 (el) | 2021-01-27 |
Family
ID=53298950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191101354T CY1122572T1 (el) | 2015-04-21 | 2019-12-23 | Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögren |
Country Status (27)
Country | Link |
---|---|
US (1) | US10493074B2 (el) |
EP (1) | EP3285772B1 (el) |
JP (1) | JP6721606B2 (el) |
KR (1) | KR102627370B1 (el) |
CN (1) | CN107530344B (el) |
AR (1) | AR105552A1 (el) |
AU (1) | AU2016251236B2 (el) |
BR (1) | BR112017020591B8 (el) |
CA (1) | CA2981631C (el) |
CL (1) | CL2017002669A1 (el) |
CO (1) | CO2017010573A2 (el) |
CY (1) | CY1122572T1 (el) |
DK (1) | DK3285772T3 (el) |
EA (1) | EA032432B1 (el) |
ES (1) | ES2763335T3 (el) |
GB (1) | GB201506786D0 (el) |
HR (1) | HRP20192273T1 (el) |
HU (1) | HUE047162T2 (el) |
IL (1) | IL254766B (el) |
LT (1) | LT3285772T (el) |
MX (1) | MX2017013148A (el) |
MY (1) | MY192972A (el) |
PL (1) | PL3285772T3 (el) |
PT (1) | PT3285772T (el) |
SG (1) | SG11201707789YA (el) |
SI (1) | SI3285772T1 (el) |
WO (1) | WO2016170014A1 (el) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201708856D0 (en) | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7932260B2 (en) * | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
KR101504773B1 (ko) * | 2007-03-23 | 2015-03-20 | 암젠 인크 | 헤테로시클릭 화합물 및 그의 용도 |
DK2496567T3 (en) * | 2009-11-05 | 2017-10-30 | Rhizen Pharmaceuticals S A | PRESENT UNKNOWN BENZOPYRANKINA MODULATORS |
UA112517C2 (uk) * | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
EA028319B1 (ru) * | 2013-06-14 | 2017-11-30 | Джилид Калистога Ллс | Ингибиторы фосфатидилинозитол-3-киназы |
-
2015
- 2015-04-21 GB GBGB1506786.1A patent/GB201506786D0/en not_active Ceased
-
2016
- 2016-04-20 EP EP16719356.4A patent/EP3285772B1/en active Active
- 2016-04-20 US US15/565,866 patent/US10493074B2/en active Active
- 2016-04-20 DK DK16719356.4T patent/DK3285772T3/da active
- 2016-04-20 WO PCT/EP2016/058810 patent/WO2016170014A1/en active Application Filing
- 2016-04-20 LT LTEP16719356.4T patent/LT3285772T/lt unknown
- 2016-04-20 EA EA201792318A patent/EA032432B1/ru not_active IP Right Cessation
- 2016-04-20 HU HUE16719356A patent/HUE047162T2/hu unknown
- 2016-04-20 SI SI201630565T patent/SI3285772T1/sl unknown
- 2016-04-20 JP JP2017554426A patent/JP6721606B2/ja active Active
- 2016-04-20 MY MYPI2017703917A patent/MY192972A/en unknown
- 2016-04-20 CN CN201680022982.1A patent/CN107530344B/zh active Active
- 2016-04-20 ES ES16719356T patent/ES2763335T3/es active Active
- 2016-04-20 PT PT167193564T patent/PT3285772T/pt unknown
- 2016-04-20 AU AU2016251236A patent/AU2016251236B2/en active Active
- 2016-04-20 CA CA2981631A patent/CA2981631C/en active Active
- 2016-04-20 PL PL16719356T patent/PL3285772T3/pl unknown
- 2016-04-20 KR KR1020177031275A patent/KR102627370B1/ko active IP Right Grant
- 2016-04-20 SG SG11201707789YA patent/SG11201707789YA/en unknown
- 2016-04-20 AR ARP160101079A patent/AR105552A1/es unknown
- 2016-04-20 BR BR112017020591A patent/BR112017020591B8/pt active IP Right Grant
- 2016-04-20 MX MX2017013148A patent/MX2017013148A/es active IP Right Grant
-
2017
- 2017-09-28 IL IL254766A patent/IL254766B/en active IP Right Grant
- 2017-10-17 CO CONC2017/0010573A patent/CO2017010573A2/es unknown
- 2017-10-20 CL CL2017002669A patent/CL2017002669A1/es unknown
-
2019
- 2019-12-17 HR HRP20192273TT patent/HRP20192273T1/hr unknown
- 2019-12-23 CY CY20191101354T patent/CY1122572T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
CY1126052T1 (el) | 1η-πυρρολο[2,3-c]πυριδιν-7(6η)-ονες και πυραζολο[3,4-c]πυριδιν-7(6η)- ονες ως αναστολεις των bet πρωτεϊνων | |
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
PH12018501589A1 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
PH12017501780A1 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
CY1121997T1 (el) | Κρυσταλλικες μορφες του 2-((4s)-6-(4-χλωροφαινυλ)-1-μεθυλ-4η-βενζο[c]ισοξαζολo[4,5-ε]αζεπιν-4-υλ)ακεταμιδιου | |
EA201992546A1 (ru) | Средства на основе антител к cd33 | |
CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CO2018013559A2 (es) | Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds) | |
PL3759083T3 (pl) | Pochodne 2,4-diaminochinazoliny i ich zastosowanie w leczeniu zakażeń wirusowych, nowotworu lub alergii | |
EP3615056A4 (en) | METHODS AND COMPOSITIONS FOR THE SCREENING AND TREATMENT OF CANCER | |
EA201792123A1 (ru) | Лечение боли | |
MX2018009499A (es) | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. | |
UY33153A (es) | Formulación tópica oftálmica de péptidos | |
IL284124A (en) | History of quinoline for use in the treatment or prevention of cancer | |
CY1122572T1 (el) | Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögren | |
EP3533451A4 (en) | APPLICATION OF PAEENIFLORIN-6'-O-BENZENE SULFONATE IN MEDICINE FOR THE TREATMENT OF SJÖGREN SYNDROME | |
WO2017095918A3 (en) | Methods for treating cancer using rspo3 antagonists | |
IT201700109607A1 (it) | Composizione per l'uso nella prevenzione e/o nel trattamento del glaucoma. | |
ITUA20162781A1 (it) | Kit di medicamenti per l’uso nel trattamento di lesioni dei tessuti tegumentari. | |
WO2016073652A8 (en) | Iminosugars useful for the treatment of viral diseases | |
CL2018001871A1 (es) | Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario | |
UA115417U (xx) | Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі |